In addition to imaging the ER and PR, a recent study demonstrated the feasibility and potential utility of imaging the androgen receptor (AR) in breast cancer, using the agent 18F-16β-18F-fluoro-5α-dihydrotestosterone [91], an agent that has been more widely tested in prostate cancer [92]. Here, ESR1 is linked to breast carcinoma.